Background Patients with acute intracerebral hemorrhage who are receiving factor Xa
inhibitors have a risk of hematoma expansion. The effect of andexanet alfa, an agent that …

Background: Andexanet alfa is a modified recombinant inactive factor Xa (FXa) designed to
reverse FXa inhibitors. ANNEXA-4 (Andexanet Alfa, a Novel Antidote to the Anticoagulation …

Background and Purpose: It is unestablished whether andexanet alfa, compared with
guideline-based usual care including prothrombin complex concentrates, is associated with …

Background Andexanet alfa (andexanet) is a recombinant modified human factor Xa decoy
protein that has been shown to reverse the inhibition of factor Xa in healthy volunteers …

Background Andexanet alfa is a modified recombinant inactive form of human factor Xa
developed for reversal of factor Xa inhibitors. Methods We evaluated 352 patients who had …

Background and Purpose: Andexanet alfa is a recombinant modified human FXa (factor Xa)
developed to reverse FXa inhibition from anticoagulants. Hemostatic efficacy and reversal of …

Objective In 2018, the FDA approved andexanet alfa for the reversal of life-threatening
hemorrhages in patients anticoagulated with apixaban or rivaroxaban. Yet, cost-effective …

Abstract Background/Objective There are limited data on the risks and benefits of using
andexanet alfa (AA) in comparison with four-factor prothrombin complex concentrate (4F …

Background: Since the approval of the oral factor Xa inhibitors, there have been concerns
regarding the ability to neutralize their anticoagulant effects after intracranial hemorrhage …

Abstract Background/Objective Before approval of andexanet alfa, off‐label treatment with 4‐
factor prothrombin complex concentrate (4F‐PCC) was often utilized for the management of …